416 related articles for article (PubMed ID: 22075489)
1. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
[TBL] [Abstract][Full Text] [Related]
2. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
4. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of procalcitonin in community-acquired pneumonia.
Schuetz P; Suter-Widmer I; Chaudri A; Christ-Crain M; Zimmerli W; Mueller B;
Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
[TBL] [Abstract][Full Text] [Related]
9. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
[TBL] [Abstract][Full Text] [Related]
10. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
[TBL] [Abstract][Full Text] [Related]
11. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
Ugajin M; Yamaki K; Hirasawa N; Yagi T
Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
[TBL] [Abstract][Full Text] [Related]
12. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.
Masiá M; Gutiérrez F; Shum C; Padilla S; Navarro JC; Flores E; Hernández I
Chest; 2005 Oct; 128(4):2223-9. PubMed ID: 16236878
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.
Kasamatsu Y; Yamaguchi T; Kawaguchi T; Tanaka N; Oka H; Nakamura T; Yamagami K; Yoshioka K; Imanishi M
Respirology; 2012 Feb; 17(2):330-6. PubMed ID: 22059525
[TBL] [Abstract][Full Text] [Related]
15. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
[TBL] [Abstract][Full Text] [Related]
16. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review.
Cavallazzi R; El-Kersh K; Abu-Atherah E; Singh S; Loke YK; Wiemken T; Ramirez J
Respir Med; 2014 Nov; 108(11):1569-80. PubMed ID: 25448309
[TBL] [Abstract][Full Text] [Related]
17. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia.
Schuetz P; Litke A; Albrich WC; Mueller B
Curr Opin Infect Dis; 2013 Apr; 26(2):159-67. PubMed ID: 23434895
[TBL] [Abstract][Full Text] [Related]
18. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
Menéndez R; Martínez R; Reyes S; Mensa J; Filella X; Marcos MA; Martínez A; Esquinas C; Ramirez P; Torres A
Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
[TBL] [Abstract][Full Text] [Related]
20. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
